Gilead Sciences reported a negative trailing twelve-month EPS of -$3.13 due to a large one-time charge in Q2 2026, but its quarterly dividend was raised to $0.82. The company’s free cash flow covers the dividend about 4.6 times, indicating strong cash support for payouts despite accounting losses. Core business growth, especially in HIV product sales, remains solid, and management expects continued revenue and earnings growth in 2028. Risks include upcoming Medicare pricing impacts and potential acquisition charges, but the dividend payout ratio under 40% suggests the dividend is secure for now.
Gilead Sciences shares show steady investor interest with 96% of Pluang users buying and a dividend yield of 1.97%. The stock trades at USD 166.89, slightly down 0.41% on the day. These figures are as of Nov 07, 2026 18:51 WIB.
